“Continuous Weekly Adalimumab Is the Optimal Long-Term Strategy for Patients With Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s129. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/76.